MHRA announces Cooperation with seven international Partners
The U.K Medicines and Healthcare products Regulatory Agency (MHRA) is working on a new international recognition framework.
The aim is to leverage the expertise of seven trusted international regulatory partners:
- Singapore Health Sciences Authority
- Swissmedic
- Health Canada
- Australia's Therapeutic Goods Administration (TGA)
- European Medicines Agency (EMA)
- Pharmaceuticals and Medical Devices Agency Japan
- U.S. FDA
According to MHRA, patients in the UK will have access to safe and effective medicines that have been approved by trusted regulatory partners in other countries. This will be made possible through new international recognition routes, which will work alongside the UK's own innovation pathway for medicines.
The new framework will allow MHRA to utilize the expertise and decision-making of trusted regulatory partners to expedite assessments of specific products. This will enable advanced medicines that have already been approved in other countries to reach UK patients more quickly.
It is important to note that the MHRA will still have the responsibility of approving all applications under the new recognition framework and retains the authority to reject applications if the provided evidence is not robust enough.
While the current announcement primarily focuses on medicines, efforts are underway to establish similar recognition routes for medical devices as well. The MHRA will initiate a targeted consultation on medical devices to gather opinions on various topics, including the recognition of conformity assessments or approvals from international regulatory partners.
These recognition routes will be in place by early 2024.
Related GMP News
15.10.2025Executing the Audit Trail Review
08.10.2025Risk-based Determination of the Scope and Frequency of Audit Trail Reviews
01.10.2025Decentralised Manufacturing: New UK Framework in Operation
24.09.2025Responsibilities for the Audit Trail (Review)
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
17.09.2025Dealing with Systems without Audit Trail Functionality